Ralmitaront

Ralmitaront (RO6889450) is an orally active agonist of trace amine-associated receptor 1 (TAAR1) with a EC50 value of 110.4 nM. Ralmitaront has antipsychotic, cognitively improvement, and antidepressant activity in rodents. Ralmitaront can be used as a neurosuppressant in the study of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder[1][2][3][4].

Product Specifications

CAS Number

[2133417-13-5]

Product Name Alternative

RO6889450

UNSPSC

12352005

Target

5-HT Receptor; Dopamine Receptor; Trace Amine-associated Receptor (TAAR)

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ralmitaront.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=NNC(CC)=C1C)NC2=CC=C([C@H]3CNCCO3)C=C2

Molecular Formula

C17H22N4O2

Molecular Weight

314.38

References & Citations

[1]Linda S Brady, et al. Redirecting the revolution: new developments in drug development for psychiatry. Expert Opin Drug Discov. 2019 Dec;14 (12) :1213-1219.|[2]Halff EF, et al. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023 Jan;46 (1) :60-74. |[3]Ågren R, et al. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450) : Two TAAR1 Agonist Candidate Antipsychotics. Int J Neuropsychopharmacol. 2023 Sep 25;26 (9) :599-606. |[4]Yu J, et al. Elucidating the molecular pharmacology of trace amine-associated receptor 1 to advance antipsychotic drug discovery. Clin Transl Med. 2024 Feb;14 (2) :e1576.